Details for Patent: 8,835,474
✉ Email this page to a colleague
Which drugs does patent 8,835,474 protect, and when does it expire?
Patent 8,835,474 protects MYRBETRIQ and is included in one NDA.
Protection for MYRBETRIQ has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirty-two patent family members in twenty-five countries.
Summary for Patent: 8,835,474
| Title: | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
| Abstract: | (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]a- cetic acid anilide or its salt shows a potent bladder relaxation effect in "isolated rat bladder smooth muscle relaxation test", dose-dependently lowers the contraction frequency of rhythmic bladder contractions in "rat rhythmic bladder contraction measurement test" and, moreover, prolongs the urination intervals in "urination functions measurement test on cyclophosphamide-induced overactive bladder model rat". Owing to these effects, the above compound is useful as a remedy for overactive bladder. |
| Inventor(s): | Takasu; Toshiyuki (Tsukubamirai, JP), Sato; Shuichi (Tsukuba, JP), Ukai; Masashi (Tsukuba, JP), Maruyama; Tatsuya (Tsuchiura, JP), Shibasaki; Masayuki (Tokyo, JP) |
| Assignee: | Astellas Pharma Inc. (Tokyo, JP) |
| Application Number: | 13/117,638 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,835,474 |
|
Patent Claim Types: see list of patent claims | Use; Delivery; |
Drugs Protected by US Patent 8,835,474
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apgdi | MYRBETRIQ | mirabegron | TABLET, EXTENDED RELEASE;ORAL | 202611-001 | Jun 28, 2012 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Apgdi | MYRBETRIQ | mirabegron | TABLET, EXTENDED RELEASE;ORAL | 202611-002 | Jun 28, 2012 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,835,474
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | 2002-323792 | Nov 7, 2002 |
International Family Members for US Patent 8,835,474
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1559427 | ⤷ Sign Up | C300599 | Netherlands | ⤷ Sign Up |
| European Patent Office | 1559427 | ⤷ Sign Up | CA 2013 00028 | Denmark | ⤷ Sign Up |
| European Patent Office | 1559427 | ⤷ Sign Up | 92218 | Luxembourg | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
